Understanding and preventing heart-related side effects of cancer treatments
Novel strategies to understand, predict, and prevent vascular toxicity of targeted CML therapies
This study is looking at how new cancer treatments for chronic myeloid leukemia might affect your heart and blood vessels, so we can find ways to keep you safe from serious heart problems while you’re being treated.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10755320 on NIH RePORTER |
What this research studies
This research investigates the vascular toxicities associated with targeted therapies for chronic myeloid leukemia (CML), particularly focusing on newer tyrosine kinase inhibitors (TKIs) that can increase the risk of serious cardiovascular events. By examining how these drugs affect endothelial cells, the research aims to identify mechanisms of toxicity and develop strategies to prevent adverse cardiovascular outcomes in patients. The study utilizes advanced techniques such as proteomics and intravital microscopy to model and analyze the effects of these therapies on blood vessels. Ultimately, the goal is to provide clinicians with data to better manage and mitigate these risks for cancer survivors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic myeloid leukemia who are being treated with newer generation tyrosine kinase inhibitors and may have underlying cardiovascular risk factors.
Not a fit: Patients who are not receiving targeted therapies for chronic myeloid leukemia or those without cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved safety and management strategies for patients undergoing treatment for chronic myeloid leukemia, reducing the risk of serious cardiovascular complications.
How similar studies have performed: Previous research has indicated that understanding the mechanisms of drug toxicity can lead to significant advancements in patient safety, suggesting that this approach has the potential for success.
Where this research is happening
Boston, United States
- Tufts Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Jaffe, Iris Z — Tufts Medical Center
- Study coordinator: Jaffe, Iris Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.